Mining 150,000 tumor RNA-seq datasets uncovers shared public TCRs against cancer antigens
- Statistical mining of routine clinical tumor RNA-seq from roughly 150,000 patients found recurrent, shared TCR chains linked to known cancer antigens, including HPV, mutant KRAS and CT83 presented on HLA.
- The authors developed ways to pair enriched alpha and beta chains into full receptors, then tested candidates for antigen recognition.
- Dozens of TCRs across nine peptide-HLA targets were validated, some with strong cytotoxic activity, suggesting public anticancer TCRs are common and a new source for TCR-based therapeutics.
💡 Points Based on the abstract
Public TCRs are attractive because one receptor could serve many patients, but the HLA restriction still caps who qualifies. What I'd want before taking any of these forward is cross-reactivity screening against a normal-peptide panel and primary tissue, since a strong in vitro kill says little about off-target risk. Mutant KRAS and CT83 differ sharply here, and in vitro cytotoxicity won't tell you which is safer.
Cancer-specific T cell receptor discovery using 150,000 clinical genomics samples ↗